SecBot SecBot

LENZ

LENZ Therapeutics, Inc.
Nasdaq· Biological Products, (No Diagnostic Substances)· Inc. DE· CIK 0001815776 Biotech & Drug Discovery
$3.14 −0.02 (−0.47%)
Oct 26 4:00 PM ET · prev $3.16
Market cap
$102.1M
Micro cap
Consensus
Buy
77% Buy or better · 13 analysts
Median target
$10.00
+218% · range $5.00–50.00
Next earnings
Oct 29
in 3 days · EPS est. −$0.95
1 year
−89.9%
from $31.29 · Oct 27
30 days
−20.6%
from $3.96
52-week range
$3.14–31.94
at the low
Avg volume 20D
742.2K
shares / day
Short interest
10.56M
≈33.6% of shares · −0.7%
Days to cover
13.8
at average volume
Insider net
+$365.6K
3 buyers · 0 sellers · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
SecBot read MIXED 3 reports · 90 days
Balance 0 bearish · 0 bullish · 1 mixed · 2 neutral oldest → newest, height = score
Avg score ·High conf. 1/3 ·Next Earnings date, Oct 29, 2026
Strongest NEUTRAL Millennium Management LLC disclosed a 3.7% passive stake in LENZ Therapeutics as of September 30, 2026, via…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBULLISH

    3 insiders bought $365.6K at an average $8.88. No open-market sales. Price is 65% below their cost.

  • InstitutionsBULLISH

    Q2 2026: 24 added (0 new), 15 trimmed or exited.

  • AnalystsBULLISH

    10 of 13 rate it Buy or better. Every target is above the price.

  • EstimatesFLAT

    Current-quarter EPS estimate −$0.942 → −$0.950 over 90 days. 4 up, 3 down in 30 days.

  • Short sellersSTEADY

    Short interest −0.7% to 10.56M shares. 13.8 days to cover, ≈33.6% of shares.

  • TrendDOWNTREND

    25% below its 50-day average. New closing low $3.14 on Oct 26.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
Aberdeen Group plcADD1,547,883$8.8M
MILLENNIUM MANAGEMENT LLCADD1,508,478$8.6M
Trexquant Investment LPDOUBLED497,526$2.8M
MARSHALL WACE, LLPDOUBLED493,099$2.8M
MORGAN STANLEYTRIM472,995$2.7M
BANK OF AMERICA CORP /DE/TRIM255,410$1.5M
VANGUARD PORTFOLIO MANAGEMENT LLCADD193,323$1.1M
Quantinno Capital Management LPDOUBLED137,715$782.2K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

13 analysts
Buy 77% rate it Buy or better
Strong Buy5Buy5Hold3Sell0Strong Sell0
12-month targets · 6 analysts

Price is below the lowest target. Median implies +218%.Targets as of Oct 26, 2026.

Recent actions
DateFirmActionRating
Oct 21, 2026TD Cowen
MAINTAIN
MAINTAINBuy
Oct 19, 2026Piper Sandler
MAINTAIN
MAINTAINNeutral
Aug 12, 2026Piper Sandler
MAINTAIN
MAINTAINNeutral
Jul 7, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
May 13, 2026Citigroup
MAINTAIN
MAINTAINBuy
May 12, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy

Insider ledger

Form 4
$365.6K
bought · 3 insiders
$0
sold · 0 insiders
−64.6%
vs their $8.88 cost
DateInsiderTypeValue
Jun 15, 2026
Guerard Frederic
Director
AWARD22,100 sh
Jun 15, 2026
MCCOLLUM JAMES W
Director
AWARD22,100 sh
Jun 15, 2026
Scheiner Zachary
Director
AWARD22,100 sh
Jun 15, 2026
Thunen Shelley B
Director
AWARD22,100 sh
Jun 15, 2026
Drapkin Kimberlee C
Director
AWARD22,100 sh
Jun 15, 2026
George Jeffrey P.
Director
AWARD22,100 sh
Jun 15, 2026
RA CAPITAL MANAGEMENT, L.P.
Director
AWARD22,100 sh
Mar 27, 2026
Schimmelpennink Evert B.
President, CEO and Secretary
BUY$251.4K

Earnings setup

Estimates
Oct 29
reports in 3 days
−$0.95
EPS estimate, this quarter
−1%
estimate change, 90 days
4↑ 3↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.95-$1.02–-$0.85+2.7%$4.2M
Next Q-$0.88-$1.24–-$0.64+5.0%$4.6M
Current FY-$4.18-$4.55–-$3.83+1.6%$16.0M
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Sep 30, 2026
10,560,869
shares short
-0.7%
vs prior settlement
13.8
days to cover
≈33.6%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 22, 2026 SEC
LENZ Therapeutics, Inc. announced it will report its Q3 2026 results on October 29, 2026.
PRESS-RELEASE — Impact 1/10
Oct 22, 2026 Earnings
LENZ Therapeutics to Report Third Quarter 2026 Financial Results on October 29, 2026
SAN DIEGO, Oct. 22, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the
Oct 21, 2026 SEC
Millennium Management LLC disclosed a 3.7% passive stake in LENZ Therapeutics as of September 30, 2026, via an amended…
SC 13G/A — Impact 4/10
Aug 11, 2026 SEC
LENZ Therapeutics reported Q2 2026 revenue of $5.5M (beating $2.4M consensus) and EPS of -$1.02 (beating -$1.07…
PRESS-RELEASE — Impact 5/10
Jun 30, 2026 Inst.
Aberdeen Group plc — ADD
1,547,883 shares ($8.8M)
Jun 30, 2026 Inst.
MILLENNIUM MANAGEMENT LLC — ADD
1,508,478 shares ($8.6M)
Jun 15, 2026 Insider
Guerard Frederic was granted 22,100 shares
Director
Jun 15, 2026 Insider
MCCOLLUM JAMES W was granted 22,100 shares
Director
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Oct 29, 2026
Earnings date
LENZ Q3 2026 Earnings Before Market Open — 2026-10-29
Recent
Oct 22, 2026
Earnings
LENZ Therapeutics to Report Third Quarter 2026 Financial Results on October 29, 2026
SAN DIEGO, Oct. 22, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pharmaceutical company focused on…
Sep 24, 2026
Press release
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
NEW YORK, Sept. 24, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of LENZ Therapeutics, Inc. ("Lenz" or the…
Sep 17, 2026
Press release
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
NEW YORK, Sept. 17, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of LENZ Therapeutics, Inc. ("Lenz" or the…
Sep 10, 2026
Press release
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
NEW YORK, Sept. 10, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of LENZ Therapeutics, Inc. ("Lenz" or the…
Sep 3, 2026
Press release
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
NEW YORK, Sept. 3, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of LENZ Therapeutics, Inc. ("Lenz" or the…

SecBot reports

8 filings · 2 press releases · 2 bullish · 0 bearish · 2 mixed · 4 neutral
All LENZ filing & press-release reports (10)